# Early Pandemic Associations of Latitude, Sunshine Duration, and Vitamin D Status with COVID-19 Incidence and Fatalities: A Global Analysis of 187 Countries

Reagan M. Mogire<sup>1,2\*</sup>

<sup>1</sup>Center for Research On Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

<sup>2</sup>Center for Clinical Research, Kenya Medical Research Institute (KEMRI), P. O. Box 54, Kisumu, 40100, Kenya

\*reaganmoseti@gmail.com

#### Abstract

In the face of the COVID-19 pandemic, understanding the interplay between environmental factors and virus spread is crucial for global preparedness strategies. This study explores how geographic latitude, sunshine duration, and vitamin D status were associated with the incidence and fatality rates of COVID-19 across 187 countries during the crucial early months of the outbreak. Data on the total number of COVID-19 cases by country were obtained from the United Nations database as of June 30, 2020. Univariate and multivariate regression analyses were conducted to determine the associations between COVID-19 cases and latitude, average hours of sunshine from January to June, and mean 25-hydroxyvitamin D (25(OH)D) levels. The average COVID-19 prevalence and mortality per million population were 2,087 and 69, respectively, with a case fatality rate of 3.19%. COVID-19 case fatality rate was positively associated with latitude ( $\beta = 0.030$ ; 95% CI: 0.008, 0.052) and negatively associated with hours of sunshine ( $\beta = -1.51$ ; 95% CI: -4.44, 1.41) and 25(OH)D levels ( $\beta = -1.51$ ; 95% CI: -4.44, 1.41) 0.054; 95% CI: -0.089, -0.019) in adjusted regression analyses. Findings were similar for COVID-19 prevalence and mortality rate. These findings indicate that higher latitude and lower 25(OH)D levels was associated with increased COVID-19 severity and mortality. While the data highlight potential links between vitamin D status and COVID-19 outcomes, causality cannot be inferred. Further research, including large-scale, well-controlled trials, is essential to determine whether vitamin D plays a definitive role in COVID-19 prevention and management.

**Keywords**: COVID-19, latitude, sunshine, vitamin D, prevalence, mortality rate, case fatality rate, early pandemic, intervention measures

### Introduction

As of 2024, the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 continues to pose significant global health challenges<sup>1,2</sup>. Despite advancements in vaccination and treatment strategies, the virus remains endemic in many regions due to factors such as viral mutations, vaccine hesitancy, and unequal access to healthcare resources<sup>3,4</sup>. The persistent circulation of COVID-19, along with the possibility of future SARS-like epidemics, underscores the urgent need to understand the factors influencing the incidence, transmission, and severity of such infectious diseases<sup>5</sup>.

COVID-19 has resulted in substantial morbidity and mortality worldwide. By October 2024, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. the World Health Organization reported over 770 million confirmed cases and nearly 7 million deaths globally<sup>1</sup>. While factors like age, sex, and underlying comorbidities (e.g., hypertension, diabetes, obesity) have been identified as key determinants of disease severity<sup>6</sup>, disparities in COVID-19 incidence and outcomes among different countries and populations suggest that additional factors may contribute to these variations<sup>7</sup>.

Notably, some countries with limited healthcare infrastructure and high population densities in Africa experienced relatively lower COVID-19 incidence and mortality rates than other countries <sup>8</sup>. In contrast, populations of African descent residing in temperate regions such as the United States and the United Kingdom have been disproportionately affected, exhibiting higher rates of severe disease and mortality compared to other ethnic groups<sup>9,10</sup>. These disparities have prompted investigations into environmental and nutritional factors, including the potential role of vitamin D status, that may influence susceptibility to and outcomes from COVID-19<sup>11,12</sup>.

Vitamin D deficiency has emerged as a potential modifiable risk factor affecting COVID-19 outcomes<sup>13,14</sup>. Vitamin D, primarily obtained through skin synthesis upon exposure to ultraviolet B (UVB) radiation from sunlight, plays a crucial role in modulating immune function<sup>15</sup>. Several studies have suggested that low vitamin D levels may be associated with an increased risk of respiratory infections, including COVID-19<sup>16,17</sup>. Moreover, geographical factors such as latitude and sunshine duration, which influence the endogenous production of vitamin D, may contribute to the observed differences in COVID-19 incidence and mortality rates across regions<sup>18</sup>.

Previous research examining the associations between COVID-19 outcomes and factors like latitude, sunshine exposure, and vitamin D status has often been limited to specific cities or regions, potentially restricting the generalizability of the findings<sup>19,20</sup>. To address this gap, a comprehensive analysis was conducted on data from 187 countries to investigate the relationships between COVID-19 prevalence, mortality rate, case fatality rate (CFR), and factors such as latitude, sunshine duration, and mean vitamin D status. Understanding these associations is critical not only for enhancing current public health interventions against COVID-19 but also for preparing for future respiratory epidemics<sup>21,22</sup>. Insights gained from this study may inform strategies for prevention and management, including nutritional interventions and policies aimed at mitigating the impact of COVID-19 and similar infectious diseases.

### Methods

This study utilized open-access COVID-19 data from the COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, available at <u>https://github.com/CSSEGISandData/COVID-19</u>. The dataset includes daily cumulative cases and deaths from January 2020, when only China had reported cases, up to June 30, 2020, covering the end of winter in the Northern Hemisphere on June 21, 2020.

COVID-19 data were primarily analyzed as of June 30, 2020, serving as the central reference point for this study. For comparative analysis, data from two additional dates—March 31 and September 30, 2020—were also examined. Multiple entries for each country, including data reported for individual states or provinces, were aggregated to provide a single, comprehensive value for each country. Country population data were obtained from the United Nations' World Population Prospects 2019 Revision<sup>23</sup>. Monthly average sunshine duration data for each country were sourced from the World Meteorological Organization (WMO)<sup>24</sup>. Mean 25-hydroxyvitamin D (250HD) levels for countries were gathered from existing literature, prioritizing national surveys, followed by community-based studies or country-level data in that order.

For the analyses, prevalence was defined as the number of COVID-19 cases per one million population in a country. The mortality rate was defined as the number of deaths per one million population. The case fatality rate (CFR) was calculated as the percentage of confirmed COVID-19 patients who died (number of deaths divided by the number of confirmed cases, multiplied by 100) in a country.

Statistical analyses were conducted using R version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria), available at https://www.R-project.org/. Variable normality was evaluated using the Kolmogorov-Smirnov test. To enable parametric analyses, numbers of COVID-19 cases and deaths, along with other parameters, were log-transformed to achieve normal distribution. However, mean values were calculated from untransformed data for descriptive statistics. Associations between COVID-19 metrics-prevalence, mortality rate, and case fatality rate—and factors such as latitude, average sunshine duration, and mean 25-hydroxyvitamin D (250HD) levels were explored using univariate and multivariate linear regression models. The multivariate models were adjusted for gross domestic product (GDP-to control for socioeconomic factors that might influence the COVID-19 outcomes and testing), elderly dependency ratio (EDR-to account for the higher impact of COVID-19 on elderly populations), and population density (to adjust for the increased transmission rates in denser populations), with data sourced from the relevant databases. Scatter plots visualized these relationships for each country, with a p-value of less than 0.05 denoting statistical significance. For analyses involving geographic position, latitudes north of the equator were coded as positive values, indicating greater distance from the equator, while southern latitudes were coded as negative, indicating proximity to the equator. This coding reflects the seasonal variation in sunlight exposure relevant until June, after which the seasons significantly change.

# Results

### **Population Characteristics**

This study analyzed data up to June 30<sup>th</sup> from 187 countries across the seven UN world regions (Figure 1 and Supplementary Figure 1). The dataset included 10,446,927 confirmed COVID-19 cases and 508, 459 deaths. The average COVID-19 prevalence and mortality rates per million population were 2,087 and 69, respectively, with an overall CFR of 3.19%.

### Effect of latitude on COVID-19 prevalence, mortality rate, and case fatality rate

Linear multivariate regression analyses demonstrated a positive correlation between latitude and COVID-19 prevalence ( $\beta = 0.012$ ; 95% CI: 0.001, 0.024), mortality rate ( $\beta = 0.042$ ; 95% CI: 0.014, 0.070), and CFR ( $\beta = 0.030$ ; 95% CI: 0.013, 0.050) (Table 2). A similar trend was observed up to the end of March 2020 but not significant in September 2020 (Supplementary Table 1). Scatter plots also showed a positive correlation between latitude and COVID-19 metrics (Figure 2A, B and C). Latitude accounted for 5%, 16%, and 4% of the variation in COVID-19 prevalence, mortality rate, and CFR, respectively by the end of June 2020 (Figure 2).

# Effect of sunshine duration on COVID-19 prevalence, mortality rate, and case fatality rate

An inverse association was observed between the average number of sunshine hours and the parameters in univariate analyses but was not significant in multivariate analyses: COVID-19 prevalence rate ( $\beta = 0.16$ ; 95% CI: -1.30, 1.62), mortality rate ( $\beta = 0.22$ ; 95% CI: -3.06, 3.50), and CFR ( $\beta = -1.51$ ; 95% CI: -4.44, 1.41). Similar effects were noted up to the end of March for prevalence and mortality rates, but the association with CFR was not significant. By the end of September, none of these associations remained significant. Scatter plots also indicated an inverse relationship between sunshine duration and COVID-19 metrics (Figure 2D, E and F). Sunshine duration explained 9.9%, 12%, and 1.4% of the variation in COVID-19 prevalence, mortality rate, and CFR, respectively (Figure 2).

# Effect of vitamin D Status on COVID-19 prevalence, mortality rate, and case fatality rate

Mean serum 25OHD) levels were inversely associated with COVID-19 mortality rate ( $\beta = -0.052$ ; 95% CI: -0.094, -0.009) and CFR ( $\beta = -0.033$ ; 95% CI: -0.061, -0.006). However, the association between 25OHD levels and COVID-19 prevalence rate was not statistically significant ( $\beta = -0.018$ ; 95% CI: -0.041, 0.005; p = 0.13). In March, mean 25OHD levels were significantly associated with mortality rate but not with prevalence or CFR (Supplementary Table 1). By the end of September, significant associations were found between mean 25OHD levels and COVID-19 mortality rate and CFR, but not with prevalence (Supplementary Table 1). Mean 25OHD levels explained 3.2%, 2%, and 2.1% of the variation in COVID-19 prevalence, mortality rate, and CFR, respectively (Figure 2).

### Discussion

This study investigated the associations between geographical factors, vitamin D status, and COVID-19 outcomes across 187 countries during the first six months of 2020. The findings indicate that the prevalence, mortality rate, and case fatality rate (CFR) of COVID-19 were positively associated with latitude and inversely associated with sunshine duration and mean 250HD levels. These associations were significant up to the end of March 2020 but diminished by the end of September, except for the inverse relationship between mean 250HD levels and COVID-19 prevalence and CFR. These results suggest potential environmental and nutritional influences on COVID-19 outcomes and highlight a temporal dimension to these relationships.

The positive association between latitude and COVID-19 metrics aligns with previous studies. Rhodes et al. (2020) reported higher mortality rates in countries above 35° North latitude compared to those below, suggesting that latitude may play a role in disease severity<sup>8</sup>. Similarly, higher COVID-19 incidence and transmission rates have been observed in cities and countries farther from the equator<sup>25,26</sup>. Benedetti et al. (2020) found that COVID-19 mortality rates were positively correlated with latitude and negatively correlated with average temperature across regions in the United States and Europe <sup>27</sup>. The influence of latitude on COVID-19 outcomes may be attributed to lower sunlight exposure during winter months at higher latitudes, leading to vitamin D deficiency <sup>15</sup>. Additionally, lower temperatures associated with higher latitudes may facilitate viral transmission, as seen in past epidemics like SARS and influenza <sup>28,29</sup>.

The inverse associations between COVID-19 prevalence, mortality rate, and CFR with average sunshine duration are consistent with previous research. Byass (2020) reported that the incidence of COVID-19 decreased with increasing solar radiation in various locations across China during January and February 2020 <sup>30</sup>. Furthermore, a study conducted in Jakarta, Indonesia, demonstrated that increased sunlight exposure improved recovery rates

among COVID-19 patients<sup>31</sup>. Reduced sunlight exposure may influence COVID-19 outcomes by affecting vitamin D synthesis, which plays a crucial role in immune function<sup>15,16</sup>.

The findings also indicated that mean 25OHD levels were inversely associated with COVID-19 mortality rate and CFR. This observation aligns with Laird et al. (2020), who reported that mean 25OHD levels in European countries were inversely associated with COVID-19 incidence and mortality rates<sup>20</sup>. Additionally, D'Avolio et al. (2020) found that patients who tested positive for SARS-CoV-2 had significantly lower mean 25OHD levels compared to those who tested negative <sup>32</sup>. Vitamin D deficiency may increase susceptibility to COVID-19 by modulating the immune response and influencing the expression of angiotensinconverting enzyme 2 (ACE2), which is involved in viral entry into cells Munshi<sup>11</sup>. Elevated ACE2 expression has been associated with increased survival in COVID-19 patients<sup>33</sup>. Moreover, vitamin D deficiency is linked to comorbidities such as hypertension, diabetes, and obesity, which are known risk factors for severe COVID-19 outcomes Sattar <sup>6,34</sup>.

The waning of the observed associations by the end of September may be attributed to the implementation of control measures, changes in testing rates, or seasonal variations. Increased public health interventions, such as lockdowns and social distancing, could have mitigated the influence of environmental factors on COVID-19 transmission <sup>3,4</sup>. Seasonal changes leading to increased sunlight exposure during the summer months may have improved vitamin D status in populations, potentially affecting disease outcomes Lips <sup>35,36</sup>.

It is important to acknowledge that, due to the observational nature of this study, causality cannot be inferred, and confounding factors may influence the relationships observed. Other variables such as government policies, healthcare capacity, socioeconomic status, and population behaviors were not accounted for and could confound the results <sup>8,37</sup>. For instance, Lawal (2021) discussed the paradox of low COVID-19 mortality rates in Africa despite limited healthcare resources, suggesting that factors like younger population demographics and prior exposure to infectious diseases may play a role<sup>8</sup>.

A major strength of this study is the inclusion of data from all countries reporting COVID-19 cases and deaths during the study period, which reduces potential selection bias. Additionally, the analysis considered multiple geographical and environmental factors, including latitude, sunshine duration, and vitamin D status, providing a comprehensive overview of potential influences on COVID-19 outcomes. However, several limitations should be acknowledged. First, the observational design limits the ability to establish causal relationships. Second, sunshine duration and mean 25OHD levels were not available for several countries, which may affect the generalizability of the findings. Third, other potential confounding factors, such as variations in testing rates, reporting practices, public health interventions, and genetic differences among populations, were not accounted for in the analysis. Furthermore, vitamin D levels were based on mean values from existing literature, which may not accurately reflect current population statuses.

This global analysis suggests that higher latitude is associated with increased COVID-19 prevalence, mortality rate, and case fatality rate during the early phase of the pandemic, while higher mean 25-hydroxyvitamin D (25OHD) levels are associated with reduced COVID-19 outcomes. These findings indicate potential environmental and nutritional influences on COVID-19 incidence and disease severity, highlighting vitamin D status as a possible contributing factor. However, recent randomized controlled trials have yielded mixed results regarding the efficacy of vitamin D supplementation in preventing or treating COVID-19.

Some studies have shown no significant benefit of high-dose vitamin D supplementation on hospital length of stay or mortality<sup>38,39</sup>, while others have suggested a reduction in severe outcomes with vitamin D administration<sup>40,41</sup>. Therefore, while observational data support a potential association between vitamin D status and COVID-19 outcomes, causality cannot be established based on current evidence. Considering the ongoing circulation of COVID-19 and the potential for future SARS-like epidemics, understanding the factors that influence disease transmission and severity remains critical. Insights from this study may inform public health strategies aimed at improving population health through safe sun exposure and addressing vitamin D deficiency where prevalent.

# Data Availability

The dataset and accompanying analysis code from the current study are available in our GitHub repository at <u>https://github.com/rmogire/COVID19-Latitude-Sunshine-VitaminD</u>. The dataset is licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License, allowing unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The analysis scripts are available under the MIT License, which permits reuse with proper attribution. Researchers and other interested parties are encouraged to access the repository to review the data and replicate the analyses. Any updates or corrections to the dataset are noted in the repository's changelog. Should there be any questions regarding the data, the corresponding author can be contacted for more information.

# **Ethics Statement**

This study utilized publicly available, aggregated data at the country level from reputable sources such as the World Health Organization and the World Bank. No individual-level or personally identifiable information was collected or analyzed. Therefore, ethical approval and informed consent were not required.

# Funding

This study was conducted without any external funding.

# **Supporting Information**

Supplementary Table 1. Effect of latitude, amount of sunshine and vitamin D status on COVID-19 prevalence, mortality rate and case fatality rate by March 31<sup>st</sup> and September 30<sup>th</sup>

Supplementary Figure 1. Prevalence (number of COVID-19 cases per one million population) of COVID-19 by country as of June 30<sup>th</sup> 2020.

Region	No. of countries	No. cases	No. of deaths	Average prevalence of cases <sup>a</sup>	Average mortality rate <sup>b</sup>	Average case fatality rate (%)
East Asia and Pacific	20	276,989	10,384	496	3	1.66
Europe & Central Asia	53	2,689,183	194,497	3210	166	4.72
Latin America & Caribbean	32	2,580,212	116,292	1938	64	3.60
Middle East & North Africa	22	865,192	20,444	4480	32	3.17
North America	3	2,738,006	136,481	3684	205	4.34
South Asia	8	993,990	24,443	1928	32	1.23
Sub-Saharan Africa	49	303,355	5,918	442	7	2.19
Total/average	187	10,446,927	508, 459	2087	69	3.19

# Table 1. Regional COVID-19 Statistics as of June 30, 2020

<sup>a</sup>COVID-19 prevalence was calculated as total number of reported cases per 1 million of population of a country, <sup>b</sup>mortality rate as number of deaths per 1 million of the population of a country and <sup>c</sup>case fatality rate as number of deaths/number of reported cases x 100.

Table 2. Effect of latitud	e, amount of sunshine and	vitamin D status or	ı COVID-19 outcomes
----------------------------	---------------------------	---------------------	---------------------

	Latitude			Sunshine			Vitamin D			
	Model	n	Beta (95% CI)	p	n	Beta (95% CI)	p	n	Beta (95% CI)	р
Prevalence <sup>a</sup>	Univariate	182	0.022 (0.005, 0.039)	0.010	128	-2.47 (-3.80, -1.15)	< 0.0001	74	-0.018 (-0.041, 0.005)	0.13
	Multivariate*	166	0.012 (0.001, 0.024)	0.041	121	0.16 (-1.30, 1.62)	0.83	74	-0.020 (-0.040, 0.001)	0.060
Mortality rate <sup>b</sup>	Univariate	182	0.056 (0.029, 0.082)	< 0.0001	128	-4.44 (-7.24, -1.63)	< 0.0001	74	-0.073 (-0.118, -0.028)	0.002
	Multivariate*	166	0.042 (0.014, 0.070)	0.004	121	0.22 (-3.06, 3.50)	0.89	74	-0.073 (-0.118, -0.028)	0.002
Case fatality rate (%) <sup>c</sup>	Univariate	185	0.031 (0.013, 0.050)	0.001	130	-3.66 (-5.98, -1.34)	0.0023	75	-0.056 (-0.089, -0.024)	0.001
	Multivariate*	166	0.030 (0.013, 0.050)	0.008	122	-1.51 (-4.44, 1.41)	0.31	74	-0.054 (-0.089, -0.019)	0.003

n; number of countries included in the analyses a COVID-19 prevalence as total number of reported cases per 1 million of population, b COVID-19 mortality rate as number of deaths per 1 million of the population and c COVID-19 case fatality rate as number of deaths/number of reported cases x 100. \*Multivariate model was adjusted for gross domestic product (GDP), elderly dependency ratio (EDR) and population density.



Figure 1. Case fatality rate (%) of COVID-19 by country as at 30<sup>th</sup> June 2020.



Figure 2. Correlations between COVID-19 metrics and environmental factors across

**countries.** Each point on the plots represents data for an individual country. The COVID-19 prevalence is defined as the total number of reported cases per 1 million population, the mortality rate as the number of deaths per 1 million population, and the case fatality rate as the percentage of reported cases resulting in death, multiplied by 100.

# References

- 1 Organization, W. H. *WHO Coronavirus (COVID-19) Dashboard*, <<u>https://covid19.who.int/</u>> (2024).
- 2 Fauci, A. S., Lane, H. C. & Redfield, R. R. Vol. 382 1268-1269 (Mass Medical Soc, 2020).
- Burki, T. K. Lifting of COVID-19 restrictions in the UK and the Delta variant. *The Lancet Respiratory Medicine* **9**, e85 (2021).
- 4 Mallapaty, S. Vaccines are curbing COVID: Data from Israel show drop in infections. *Nature* **590**, 197-198 (2021).
- 5 Woolhouse, M., Scott, F., Hudson, Z., Howey, R. & Chase-Topping, M. Human viruses: discovery and emergence. *Philosophical Transactions of the Royal Society B: Biological Sciences* **367**, 2864-2871 (2012).
- 6 Jordan, R. E., Adab, P. & Cheng, K. K. Vol. 368 (British Medical Journal Publishing Group, 2020).
- 7 Ssentongo, P., Ssentongo, A. E., Heilbrunn, E. S., Ba, D. M. & Chinchilli, V. M. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. *PloS one* 15, e0238215 (2020).
- 8 Lawal, Y. Africa's low COVID-19 mortality rate: A paradox? *International journal of infectious diseases* **102**, 118-122 (2021).
- 9 Kirby, T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. *The Lancet Respiratory Medicine* **8**, 547-548 (2020).
- 10 England, P. H. Disparities in the risk and outcomes of COVID-19 (Public Health England, 2020).
- 11 Munshi, R. *et al.* Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. *Journal of medical virology* **93**, 733-740 (2021).
- 12 Meltzer, D. O., Best, T. J., Zhang, H., Vokes, T., Arora, V. & Solway, J. Association of vitamin D deficiency and treatment with COVID-19 incidence. *MedRxiv*, 2020-2005 (2020).
- 13 Grant, W. B. *et al.* Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients* **12**, 988 (2020).
- 14 D'Avolio, A. *et al.* 25-Hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. *Nutrients* **12**, 1359 (2020).
- 15 Holick, M. F. Vitamin D deficiency. *New England journal of medicine* **357**, 266-281 (2007).
- 16 Martineau, A. R. *et al.* Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *bmj* **356** (2017).
- 17 Daneshkhah, A., Eshein, A., Subramanian, H., Roy, H. K. & Backman, V. The role of vitamin D in suppressing cytokine storm in COVID-19 patients and associated mortality. *MedRxiv* (2020).
- 18 Rhodes, J. M., Subramanian, S., Laird, E. & Kenny, R. A. Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. *Aliment Pharmacol Ther* **51**, 1434-1437 (2020). <u>https://doi.org:10.1111/apt.15777</u>

- Ilie, P. C., Stefanescu, S. & Smith, L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clin Exp Res* 32, 1195-1198 (2020). <u>https://doi.org:10.1007/s40520-020-01570-8</u>
- 20 Laird, E., Rhodes, J. & Kenny, R. A. Vitamin D and Inflammation: Potential Implications for Severity of COVID-19. *Ir Med J* **113**, 81 (2020).
- 21 Morens, D. M., Daszak, P. & Taubenberger, J. K. Escaping Pandora's box—another novel coronavirus. *New England Journal of Medicine* **382**, 1293-1295 (2020).
- 22 Gao, G. F. From "A" IV to "Z" IKV: attacks from emerging and re-emerging pathogens. *Cell* **172**, 1157-1159 (2018).
- United Nations, D. o. E. a. S. A., Population Division. World Population Prospects 2019.
  (2019).
- 24 World Meteorological Organization. World Weather Information Service.
- Panarese, A. & Shahini, E. Letter: COVID-19, and vitamin D. *Aliment Pharmacol Ther* 51, 993-995 (2020). <u>https://doi.org:10.1111/apt.15752</u>
- 26 Sajadi, M. M., Habibzadeh, P., Vintzileos, A., Shokouhi, S., Miralles-Wilhelm, F. & Amoroso, A. Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease 2019 (COVID-19). *JAMA Netw Open* 3, e2011834 (2020). https://doi.org:10.1001/jamanetworkopen.2020.11834
- 27 Benedetti, F. *et al.* Inverse correlation between average monthly high temperatures and COVID-19-related death rates in different geographical areas. *J Transl Med* **18**, 251 (2020). <u>https://doi.org:10.1186/s12967-020-02418-5</u>
- 28 Fan, Y., Zhao, K., Shi, Z.-L. & Zhou, P. Bat coronaviruses in China. Viruses 11, 210 (2019).
- 29 Lowen, A. C., Mubareka, S., Steel, J. & Palese, P. Influenza virus transmission is dependent on relative humidity and temperature. *PLoS pathogens* **3**, e151 (2007).
- 30 Byass, P. Eco-epidemiological assessment of the COVID-19 epidemic in China, January-February 2020. *Glob Health Action* **13**, 1760490 (2020). https://doi.org:10.1080/16549716.2020.1760490
- 31 Asyary, A. & Veruswati, M. Sunlight exposure increased COVID-19 recovery rates: A study in the central pandemic area of Indonesia. *Sci Total Environ* **729**, 139016 (2020). https://doi.org:10.1016/j.scitotenv.2020.139016
- 32 D'Avolio, A. *et al.* 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. *Nutrients* **12** (2020). <u>https://doi.org:10.3390/nu12051359</u>
- 33 Wösten-van Asperen, R. M. *et al.* Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist. *The Journal of pathology* **225**, 618-627 (2011).
- 34 Sattar, N. *et al.* BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 14, 1149-1151 (2020).
- 35 Lips, P. *et al.* Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. *European journal of endocrinology* **180**, P23-P54 (2019).
- 36 Jääskeläinen, T. *et al.* The positive impact of general vitamin D food fortification policy on vitamin D status in a representative adult Finnish population: evidence from an 11-y follow-up based on standardized 25-hydroxyvitamin D data. *The American journal of clinical nutrition* **105**, 1512-1520 (2017).

- 37 Kontis, V. *et al.* Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries. *Nature medicine* **26**, 1919-1928 (2020).
- 38 Murai, I. H. *et al.* Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. *Jama* **325**, 1053-1060 (2021).
- 39 Jolliffe, D. A. *et al.* Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and COVID-19: phase 3 randomised controlled trial (CORONAVIT). *bmj* **378** (2022).
- 40 Castillo, M. E. *et al.* Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. *The Journal of steroid biochemistry and molecular biology* **203**, 105751 (2020).
- 41 Hariyanto, T. I., Intan, D., Hananto, J. E., Harapan, H. & Kurniawan, A. (Wiley Online Library, 2022).